Clinical Trials
144 trialsMAHOGANY
BeOne Medicines
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
MK-2140-010
Merck Sharp & Dohme LLC
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene
OLYMPIA-1
Regeneron Pharmaceuticals
MANGROVE
BeOne Medicines
BELLWAVE-010
Merck Sharp & Dohme LLC
OLYMPIA-3
Regeneron Pharmaceuticals
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
OLYMPIA-4
Regeneron Pharmaceuticals
CaDAnCe-302
BeOne Medicines
CaDAnCe-303
BeOne Medicines
POLARIX
Hoffmann-La Roche
SUNMO
Hoffmann-La Roche
OLYMPIA-5
Regeneron Pharmaceuticals
EPCOREâ„¢FL-2
Genmab
Celestimo
Hoffmann-La Roche
GLOBRYTE
Hoffmann-La Roche
A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Sinocelltech Ltd.
LOTIS 5
ADC Therapeutics S.A.
BRUIN CLL-321
Eli Lilly and Company
SYMPHONY-1
Ipsen
ECHELON-3
Seagen Inc.
LEDA
Novartis
EPCORE DLBCL-4
Genmab
frontMIND
Incyte Corporation
A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL
Hutchmed
ESCALADE
Acerta Pharma BV
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular Lymphoma
Pharmacyclics LLC.
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC
SEQUOIA
BeOne Medicines
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca
CRISTALLO
Hoffmann-La Roche
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV
GOLSEEK-1
Celgene
OLYMPIA-2
Regeneron Pharmaceuticals
BRUIN CLL-322
Eli Lilly and Company
BRUIN CLL-313
Eli Lilly and Company
POLARGO
Hoffmann-La Roche
InMIND
Incyte Corporation
A Phase 3 Clinical Study of SHR-A1912 Combined With R-GemOx Versus R-GemOx in Diffuse Large B-cell Lymphoma
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
ZUMA-22
Gilead Sciences
CHRONOS-3
Bayer
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.
A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)
Incyte Corporation
EPCORE FL-1
Genmab
MAGNIFY
Celgene